WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the appointment of Theresa G. Wingrove, Ph.D. as Vice President of Regulatory Affairs. Dr. Wingrove will be responsible for leading the regulatory development of the Company’s product candidates and directing the regulatory submissions prepared by ImmunoGen in support of the Company’s own programs and those of its partners. Dr. Wingrove reports to Daniel Junius, President and Chief Executive Officer.
